TABLE 4.
Total number of cancers, standardized incidence rates, and standardized incidence ratios (SIR) relative to U.S. population, in a cohort of 4,198 2-year breast cancer survivors
| Cancer sites | Cases | Expecteda | SIR | 95 % CI |
|---|---|---|---|---|
| All sitesb | 286 | 98 | 2.91 | 2.57–3.24 |
| Lung | 38 | 21 | 1.84 | 1.25–2.42 |
| Brain | 5 | 2 | 2.54 | .31–4.76 |
| Thyroid | 21 | 6 | 3.72 | 2.13–5.30 |
| Melanoma | 24 | 6 | 4.30 | 2.58–6.02 |
| Ovarian | 29 | 5 | 6.05 | 3.84–8.25 |
| Uterine | 30 | 9 | 3.38 | 2.17–4.58 |
| Cervical | 12 | 3 | 3.98 | 1.73–6.24 |
| Sarcoma (soft tissue and bone) | 4 | 1 | 3.07 | .06–6.08 |
| Leukemia | 15 | 4 | 4.16 | 2.05–6.26 |
| Lymphoma | 23 | 7 | 3.27 | 1.93–4.61 |
| Bladder | 4 | 8 | .52 | .01–1.03 |
| Renal cell | 17 | 4 | 4.35 | 2.28–6.42 |
95 % CI 95 %confidence interval
a
Expected cases were calculated using incidence rates based on NAACCR publication cancer incidence in North America, 2002–2006, cancer incidence rate for females in United States25
b
Incidence rates for breast cancer are deduced from total incidence rates